Circulating tumor DNA - Current state of play and future perspectives

Area of Science:

• Oncology
• Molecular Diagnostics
• Biotechnology

Background:

• Personalized cancer management is advancing with -omics technologies.
• Liquid biopsies are emerging as a viable alternative to traditional tumor tissue biopsies.
• Circulating tumor DNA (ctDNA) is a key component of the "tumor circulome" found in liquid biopsies.

Purpose of the Study:

• To review the current applications of circulating tumor DNA (ctDNA) analysis.
• To discuss the clinical significance and technological advancements in ctDNA detection.
• To identify limitations and future directions for ctDNA-based cancer diagnostics.

Main Methods:

• Analysis of circulating tumor DNA (ctDNA) from liquid biopsies (blood, urine, saliva).
• Quantitative and qualitative ctDNA assessment using PCR, dPCR, whole genome sequencing, and methylation mapping.
• Review of current and emerging technologies for ctDNA analysis.

Main Results:

• ctDNA analysis demonstrates significant potential across all cancer staging and management levels.
• FDA approval for companion diagnostics highlights the clinical utility of ctDNA.
• Various technologies are available for sensitive and specific ctDNA detection.

Conclusions:

• Liquid biopsies, particularly ctDNA analysis, are revolutionizing cancer diagnosis and monitoring.
• Ongoing technological developments aim to overcome current limitations for broader clinical application.
• ctDNA analysis holds immense promise for the future of personalized oncology.